Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: Local tumor response and early followup results

M. Maffezzini, T. Torelli, E. Villa, P. Corrada, A. Bolognesi, G. L. Leidi, P. Rigatti, B. Campo

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 44 patients with infiltrating, locally advanced bladder cancer (stages T 3a-b, T 4a-b and N+/N0) were treated with the systemic chemotherapy regimen of cisplatin, methotrexate and vinblastine (CMV) in the neoadjuvant setting, of whom 39 were evaluable for response. After planned radical cystectomy and 2 to 3 cycles of chemotherapy no tumor was found on the pathological specimen of 4 patients (10%), the tumor was downstaged in 19 (49%) and no change was observed in 16 (41%). Toxicity included leukopenia in 29 patients (66%), 1 of whom died of granulocytopenic sepsis, nausea and vomiting in 39 (89%) and mild to moderate mucositis in 18 (41%). Median followup is 12 months with a range of 6 to 39 months. Of 32 patients followed for longer than 6 months 6 (19%) experienced progression or recurrence of disease. We conclude that preoperative CMV chemotherapy is effective in inducing downstaging of the tumor, although systemic toxicity limits its use to cautiously selected patients.

Original languageEnglish
Pages (from-to)741-743
Number of pages3
JournalJournal of Urology
Volume145
Issue number4
Publication statusPublished - 1991

Keywords

  • Bladder
  • Carcinoma, transitional cell
  • Combination
  • Drug therapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: Local tumor response and early followup results'. Together they form a unique fingerprint.

Cite this